Acute lymphoblastic leukemia treatment cost in China typically includes specialized diagnostics and intensive therapies. Essential procedures like allogenic bone marrow transplantation from a related donor range from $60,000 to $70,000, while autologous bone marrow transplantation runs from $22,000 to $42,000. Total expenses depend on the leukemia subtype, treatment phase, and hospital level. Patients often save 50-70% compared to US prices. Beijing, Guangzhou, and Shanghai are top cities for this treatment.
Typical Acute Lymphoblastic Leukemia Treatment Costs in China
Bookimed Expert Insight: Patients with high-risk or relapsed leukemia should prioritize JCI-accredited centers like Sun Yat-sen University Cancer Center. These institutions offer advanced digital pathology and proton-beam therapy for complex cases. For those seeking cost-effective stem cell protocols, Boao International Medical Center provides multidisciplinary care for both adults and children. Beijing-based hospitals like Lu Daopei specialize in hematology oncology, making them ideal for specialized CAR-T cell consultations.
| China | Turkey | Austria | |
| Chemotherapy for breast cancer | ≈ $14,800 | from $3,900 | ≈ $9,500 |
| Bone marrow transplantation | ≈ $38,000 | from $30,000 | ≈ $62,000 |
| Autologous bone marrow transplantation | ≈ $22,000 | from $28,000 | ≈ $38,000 |
| Allogenic bone marrow transplantation from an unrelated donor | ≈ $38,000 | from $65,000 | ≈ $105,000 |
| Allogenic bone marrow transplantation from a related donor | from $60,000 | from $53,800 | ≈ $95,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Acute lymphoblastic leukemia treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Acute lymphoblastic leukemia treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Acute lymphoblastic leukemia treatment journey.
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Dr. Ding Yi is the Associate Chief Physician in Hematology at Shanghai Tongji Hospital. She is also the acting deputy director of the Blood Transfusion Department. She holds a Master of Medicine from Tongji University. She serves on the Youth Committee of the Shanghai Society of Hematology.
She is skilled in diagnosing and treating leukemia, lymphoma, and myeloma. She offers hematopoietic and umbilical cord blood stem cell therapies. She specializes in acute leukemia. She developed sequential treatment protocols. She participated in research that won the Second Prize of the Shanghai Science and Technology Progress Award. She has published more than 10 papers.